Sakar Healthcare Limited shares surged over 11% on September 1, 2026, reaching a fresh all-time high of ₹999.00. According to latest market data, the stock opened at ₹866.30 against its previous close of ₹863.35, with the day's high showing a gain of 15.72%. The rally was driven by the company's announcement of multiple regulatory approvals across key overseas markets. As of September 1, 2026, the stock was trading at ₹965.75, representing an 11.87% increase from the previous close.
The company received approvals for five additional product site variations from the European Medicines Agency (EMA), bringing the total to six out of eight technology transfers initiated with Sakar Healthcare Limited. As reported by Dalal Street Investment Journal, two other partners based in the UK and Germany secured approvals for three products from the Medicines and Healthcare products Regulatory Agency (MHRA) and EMA. Separately, six of Sakar Healthcare Limited's licensed-out products received marketing authorizations, with four approved in the European Union, one each in the UK and Canada.
Sakar Healthcare, incorporated in 2004, operates as a Small Cap company with a market capitalization of ₹2,148.79 crore in the Hospitals & Allied Services sector. The company's 52-week high stands at ₹999.00 while the 52-week low is ₹321.05, indicating significant volatility. The stock's PE ratio stands at 53.21 and PB ratio is 5.92, reflecting its current market position. The company's annual revenue growth of 41.99% has outperformed its 3-year CAGR of 22.3%, demonstrating strong growth momentum.
The approvals significantly strengthen Sakar Healthcare's oncology portfolio, covering multiple cancer categories including breast, lung, prostate, stomach, head and neck, colon and rectum, ovary, liver, kidney and thyroid cancers, along with blood, bone marrow and lymph-related cancers. According to the company's statement, this progress in regulated markets will help leverage both its business models and support top-line growth. The company has evolved from a contract manufacturer into an API-integrated pharmaceutical company with capabilities across oral solids, injectables and oncology formulations.
